These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 30395717)

  • 1. Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
    Boland P; Wu J
    Chin Clin Oncol; 2018 Oct; 7(5):50. PubMed ID: 30395717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
    Dika IE; Abou-Alfa GK
    Clin Mol Hepatol; 2017 Dec; 23(4):273-279. PubMed ID: 29151326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
    Mody K; Abou-Alfa GK
    Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapies for hepatocellular carcinoma.
    Ge S; Huang D
    Drug Discov Ther; 2015 Oct; 9(5):352-62. PubMed ID: 26632544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
    Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
    JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy of hepatocellular carcinoma: current and promising.
    Kalyan A; Nimeiri H; Kulik L
    Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Angiogenesis in Hepatocellular Carcinoma.
    Morse MA; Sun W; Kim R; He AR; Abada PB; Mynderse M; Finn RS
    Clin Cancer Res; 2019 Feb; 25(3):912-920. PubMed ID: 30274981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
    Gao JJ; Shi ZY; Xia JF; Inagaki Y; Tang W
    World J Gastroenterol; 2015 Nov; 21(42):12059-70. PubMed ID: 26576091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
    Sharma R; Motedayen Aval L
    Front Immunol; 2021; 12():652007. PubMed ID: 33790915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapies in hepatocellular carcinoma: present and future.
    Bertino G; Di Carlo I; Ardiri A; Calvagno GS; Demma S; Malaguarnera G; Bertino N; Malaguarnera M; Toro A; Malaguarnera M
    Future Oncol; 2013 Oct; 9(10):1533-48. PubMed ID: 24106903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
    Mohr R; Jost-Brinkmann F; Özdirik B; Lambrecht J; Hammerich L; Loosen SH; Luedde T; Demir M; Tacke F; Roderburg C
    Front Immunol; 2021; 12():652172. PubMed ID: 33859646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
    Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
    Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.
    da Motta Girardi D; Correa TS; Crosara Teixeira M; Dos Santos Fernandes G
    J Gastrointest Cancer; 2018 Sep; 49(3):227-236. PubMed ID: 29806062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):1-8. PubMed ID: 24457121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.